Dual checkpoint blockade promising as pre-surgical approach for certain patients with localized bladder cancer

(University of Texas M. D. Anderson Cancer Center) Phase I trial finds neoadjuvant combination checkpoint inhibitors (anti-CTLA-4 plus anti-PD-1) was well tolerated and showed early signs of activity in certain patients with bladder cancer. These patients cannot be treated with chemotherapy and have no standard treatment options available.